Compare McDonald's Corp (MCD) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McDonald's Corp vs Recursion Pharmaceuticals Inc — how do they compare? McDonald's Corp trades at $265.2 (market cap $190.16B), while Recursion Pharmaceuticals Inc trades at $3.06 (market cap $1.53B). The key difference: McDonald's Corp is far larger — about 124.3× Recursion Pharmaceuticals Inc's market cap, and McDonald's Corp pays a 2.78% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| MCD | RXRX | |
|---|---|---|
Market Cap | $190.16B | $1.53B |
Volume | 2,230,036 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $341.06 | $6.79 |
52-Week Low | $264.54 | $2.84 |
Enterprise Value | $243.87B | $946.50M |
Dividend Yield | 2.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McDonald's (MCD) trades at $267.71, down 2.1% on the day, with a bearish technical signal driven by moving averages. The company reported steady revenue growth to $26.89 billion in 2025 and a net income margin of 31.62%, though Q2 2026 earnings are pending. Recent news highlights a new 'McDonald's NEXT' strategy focusing on automation and menu improvements to boost competitiveness.
The stock presents a buying opportunity with a consensus price target of $329, implying 23% upside, supported by strong analyst sentiment (58% buy ratings). Risks include inflationary pressures on franchisee margins and high long-term debt of $38.42 billion. Earnings execution and strategy rollout will be key for near-term performance.
RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.
The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
